Application of Blinatumomab in treatment of pediatric refractory/relapsed B-lineage acute lymphoblastic leukemia in 2 cases
10.3760/cma.j.cn101070-20210908-01096
- VernacularTitle:贝林妥欧单抗治疗难治/复发儿童急性B淋巴细胞白血病2例
- Author:
Feng ZHANG
1
;
Mingming DING
;
Aidong LU
;
Yueping JIA
;
Leping ZHANG
Author Information
1. 北京大学人民医院儿科，北京 100044
- Keywords:
Blinatumomab;
Acute lymphoblastic leukemia;
Child;
Relapse/refractory;
Immunotherapy
- From:
Chinese Journal of Applied Clinical Pediatrics
2022;37(17):1341-1343
- CountryChina
- Language:Chinese
-
Abstract:
The clinical data of two children with refractory/relapsed acute B-lymphoblastic leukemia (ALL-B)treated with Blinatumomab in Department of Pediatrics, Peking University People′s Hospital from September 2019 to May 2021 were retrospectively analyzed.After 1 course of Blinatumomab infusion, both children achieved complete hematologic remission.During the infusion process, grade 2 cytokine release syndrome (CRS) was observed, and there were no fatal adverse reactions.One case underwent bridging hematopoietic stem cell transplantation after remission and achieves disease-free survival currently.The other case is still alive after subsequent consolidation chemotherapy.As a novel bispecific antibody, Blinatumomab has a good response rate to refractory/relapsed ALL-B and induces fewer adverse events, so it can be used as a candidate immunotherapy for patients with high tumor burden.
